Clinical trials: sargramostim, completed
Lymphoma
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
RATIONALE: Vaccines made from gene-modified cells and a person's cancer cells may make the body build an effective immune response to kill cancer cells.
- Trial name
- NCT00101101
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00040937
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- 141 sites in United States
- Volunteers
- 147 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Prostate Carcinoma, Stage I Prostate Cancer
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from…
- Conditions
- Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT00108732
- Testing
- Bicalutamide, Goserelin Acetate, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms, Fever
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
This is a prospective, randomized Phase III trial of FLAC chemotherapy with GM-CSF versus PIXY321 in advanced breast cancer. The primary endpoints of this study will be the duration of thrombocytopenia and the time to recovery of…
- Conditions
- Breast Neoplasms, Fever, Hematologic Diseases, Neutropenia
- Trial name
- NCT00001338
- Testing
- FLAC chemotherapy with GM-CSF
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Triple-Negative Breast Cancer
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of tiragolumab in combination with atezolizumab and chemotherapy in participants with metastatic and early triple-negative breast cancer (TNBC).
- Trial name
- NCT04584112
- Testing
- Tiragolumab, Atezolizumab, Nab-paclitaxel
- Where
- 24 sites in United States, Australia and 6 more
- Volunteers
- 83 people
- Sponsor
- Hoffmann-La Roche
Malignant Melanoma
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancers, and in combination with ipilimumab in malignant melanoma.
- Trial name
- NCT03538314
- Testing
- UV1, GM-CSF
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Ultimovacs ASA
Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma
Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma.
- Conditions
- Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma, Childhood Malignant Mesenchymoma
- Trial name
- NCT00003958
- Testing
- dactinomycin, vincristine sulfate, cyclophosphamide
- Where
- United States
- Volunteers
- 702 people
- Sponsor
- Children's Oncology Group
Mycobacterium Avium-Intracellulare Infection
Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection
Mycobacterium avium complex (MAC) are ubiquitous organisms that cause isolated pulmonary disease in otherwise healthy patients with yet undefined susceptibilities.
- Trial name
- NCT00111397
- Testing
- Cytokine therapy, Interferon Gamma, GM-CSF
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ependymoma, Recurrent Childhood, Ependymoma
Study of the Effect of GM-CSF on Macrophages in Ependymoma
This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulation Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is…
- Trial name
- NCT04408092
- Testing
- Granulocyte Macrophage Colony Stimulation Factor
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Colorado, Denver
Breast Cancer
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
The study will be a multi-center, prospective, randomized, single-blinded, placebo-controlled Phase II trial of Herceptin + NeuVax(TM) vaccine (E75 peptide/granulocyte macrophage-colony stimulating factor) (GM-CSF) versus…
- Trial name
- NCT01570036
- Testing
- Herceptin, NeuVax vaccine, GM-CSF
- Where
- 29 sites in United States
- Volunteers
- 275 people
- Sponsor
- George E. Peoples
Prostate Cancer
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
This is a randomized, multicenter, single blind, Phase 2 trial of immunotherapy in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen
- Trial name
- NCT00715078
- Testing
- sipuleucel-T
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Dendreon
COVID-19
A Phase II/III Study of Sargramostim
This is a randomized, placebo-controlled, double-blind, group comparison, multicenter study to evaluate the efficacy and safety of inhalation administration of sargramostim for 5 days, in principle (up to 10 days) as Add-on…
- Trial name
- NCT04642950
- Testing
- Sargramostim
- Where
- 7 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Nobelpharma
Melanoma (Skin)
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies such as sargramostim and interferon alfa use different ways to stimulate the immune system and stop cancer cells from…
- Trial name
- NCT00006385
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- 32 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer, Esophageal Cancer
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT00003125
- Testing
- ALVAC-CEA vaccine, aldesleukin, sargramostim
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Georgetown University
Leukemia
Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00005948
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- 2 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
This trial is designed to investigate the efficacy and safety of GM-CSF used as a maintenance program in patients with androgen-independent prostate cancer (AIPC) who have achieved a maximal response on a taxotere or other…
- Trial name
- NCT00274287
- Testing
- GM CSF
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Oncology Specialists, S.C.
Infertility
Effects of Embryogen in RIF Patients
The purpose of this study was to investigate the potential effects of Granulocyte-Macrophage Stimulating-Colony Factor (GM-CSF) supplementation in embryo culture for patients with repeated implantation failure (RIF)
- Trial name
- RIF (NCT02250768)
- Testing
- GM-CSF
- Where
- 2 sites in Vietnam
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Vietnam National University
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known what preparation of vaccine therapy is most effective for treating melanoma.
- Trial name
- NCT00003274
- Testing
- gp100 antigen, incomplete Freund's adjuvant, sargramostim
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Southern California
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7)
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
This phase II trial is studying how well giving MS-275 together with GM-CSF works in treating patients with myelodysplastic syndrome and/or relapsed or refractory acute myeloid leukemia.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00462605
- Testing
- entinostat, sargramostim
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
This phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic).
- Conditions
- Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor
- Trial name
- NCT03879694
- Testing
- Incomplete Freund's Adjuvant, Octreotide Acetate, Sargramostim
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Roswell Park Cancer Institute